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This is the first reported case of a patient with both non-ketotic
hyperglycinemia and propionic acidemia. At 2 years of age, the
patient was diagnosed with non-ketotic hyperglycinemia by elevated
glycine levels and mutations in the GLDC gene (paternal allele:
c.1576_1577insC delT and c.1580delGinsCAA; p.S527Tfs*13, and
maternal allele: c.1819GNA; p.G607S). At 8 years of age after having
been placed on ketogenic diet, he became lethargic and had severe
metabolic acidosis with ketonuria. Urine organic acid analysis and
plasma acylcarnitine profile were consistent with propionic acidemia.
He was found to have an apparently homozygous mutation in the
PCCB gene: c.49CNA; p.Leu17Met. The patient was also treated with
natural protein restriction, carnitine, biotin, and thiamine and had
subjective and biochemical improvement.
© 2014 The Authors. Published by Elsevier Inc. This is an open access






Despite our effort to classify all of an individual's findings under one genetic or metabolic diagnosis,
individuals can have more than one disorder. Whole exome studies have illustrated the possibility of more
than one diagnosis within a single complex patient. However, how often do we think about more than one
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biochemical cause and thus, pursue further evaluations to examine more than one cause explaining
findings in a single patient? Here, we present a patient who has non-ketotic hyperglycinemia (NKH) and a
delayed diagnosis of propionic acidemia (PA).
Elevations in plasma or serum glycine can be several different disorders including non-ketotic
hyperglycinemia or ketotic hyperglycinemia. Non-ketotic hyperglycinemia (NKH) is a neurobiochemical
disorder in which the glycine cleavage system (encoded by the genes GLDC, AMT, and GCSH) is unable to
function resulting in elevated glycine [1]. Patients with NKH often present in the neonatal period with
lethargy and seizures. Furthermore, patients with an attenuated form of NKH can present later in infancy,
have variable degree of developmental delays, hyperactivity, and choreatic movements. Individuals with
NKH have elevated levels of glycine in plasma and in CSF and have an elevated CSF:plasma glycine ratio.
Typically, they do not have ketones in plasma or urine [1].
In contrast, ketotic hyperglycinemia, predominately caused by the organic acidurias, propionic
acidemia, (PA, from mutations in the genes PCCA and PCCB) and the methylmalonic acidurias (MMAs),
presents with increased ketones in urine and serum [2]. Individuals with PA have characteristic elevations
in the organic acids, 3-hydroxypropionic acid and methylcitrate, but can also have increased plasma
glycine levels. These individuals usually present with ketoacidosis and symptoms such as lethargy,
vomiting and can develop coma [2,3]. Seizures can occur, but usually during acidosis episodes [4].
2. Case report
Several hints presented throughout the history of this patient indicate that there may bemore than one
cause of his symptomatology. These included a need for carnitine at one year of life and multiple episodes
of metabolic ketoacidosis.
The patient's birth history was unremarkable with normal growth parameters, but he had poor breast
feeding early on requiring readmission for dehydration and was started on formula. At one month of age,
the patient presented with seizures. He had a normal brain MRI, an EEG with “a left focal seizure focus”,
and he was treated with phenobarbital and valproate. By 2 months of age, the infant demonstrated upper
extremity extensions, eye rolling, and repetitive mouth movements. These movements did not correlate
with seizures on video EEG, although the EEG demonstrated right and left hemispheric sharp and slow
waves.
By 1 year of age, the EEG showed hypsarrhythmia and the patient was diagnosed with intractable
seizures and epileptic encephalopathy. He was admitted with metabolic acidosis with a low bicarbonate of
2.5 mmol/L, fever, and continued to have seizures. By history, hewas also diagnosedwith low total and free
carnitine levels, and started on supplementationwith carnitine. Biochemical testingwas reportedly done at
this time at another institution, including urine organic acids and they were reportedly not diagnostic.
At 2 years of age, patient was found to have choreiform-like movements. He was diagnosed with NKH
after finding elevated glycine levels in plasma and CSF with an elevated ratio of CSF: plasma glycine. The
diagnosis was confirmed by identification of two mutations in the GLDC gene: paternal: c.1576_1577insC
delT and c.1580delGinsCAA; p.S527Tfs*13, and a missense mutation on the maternal allele c.1819GNA;
p.G607S. This mutation affects a fully conserved amino acid, is predicted to be deleterious by Polyphen-2
[5], and has been observed in another patient with NKH (Van Hove, unpublished observation).
Between the ages of 1 and 8 years, the patient had multiple hospitalizations for metabolic acidosis and
ketosis. He made little developmental progress resulting in an inability to ambulate and no functional
speech. At 8 years of age after being placed on ketogenic diet for better seizure management, he became
lethargic and had severe metabolic acidosis with ketonuria. Urine organic acid analyses were repeated and
showed a large peak of 3-hydroxypropionic acid (Fig. 1A), and the acylcarnitine profile revealed elevated
propionylcarnitine at 1.2 μmol/L (age normal b 0.88 μmol/L) (Table 1).
The patient was treated with natural protein restriction, carnitine, biotin, and thiamine with resolution
of the metabolic acidosis and of the propionate metabolites in the urine organic acids profile (Fig. 1B). Very
few differences are apparent in other metabolic measures (Table 1).
The diagnosis of propionic acidemia was confirmed by finding an apparently homozygous mutation in
the PCCB gene: c.49CNA; p.Leu17Met. There was no normal sequence identified in this sample. This change
has been described in one other patient who had an additional twomutations. However, this amino acid is
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not conserved across species. Our patient's parents deny consanguinity and father was not available for
further testing.
For our patient, subjective long term improvement was reported by his parents with increased level of
alertness despite very small changes on laboratory. His teachers felt that hemademore progress in the one
year following addition of treatment for PA, than he had made in the previous 3 years. Moreover, he
completed his goals for one year within 4 months requiring a revision of his individual education plan.
Therefore, addition of therapy for PA improved his well-being and further supports the diagnosis of PA in
addition to NKH.
Tracheostomy was placed for central and obstructive apnea at 9 1/2 years. Unfortunately, our patient
passed away at home 1 week after the procedure of an unknown cause. He was biochemically stable at
discharge.
3. Discussion
This patient presented with attenuated classic non-ketotic hyperglycinemia which was late onset,
should lead to mild developmental delay, a seizure disorder and chorea since it was caused by a typically
mild missense mutation identified in GLDC. However, unusual for a patient diagnosed with NKH, he had a
number of hospitalizations with metabolic acidosis and ketonuria, indicating a more complex problem.
Moreover, he was severely delayed with no functional speech and lack of ambulation.
The institution of the metabolic stress of a ketogenic diet resulted in metabolic decompensation
resulting in the identification of abnormal excretion of urine organic acids typical of propionic acidemia,
such as 3-hydroxypropionic acid. The dysfunction of the propionyl-CoA carboxylase in this patient was
Table 1
Selected biochemical laboratory results of our patient on ketogenic and following initiation of treatment for PA as well as the normal
ranges for our laboratory.
Laboratory Our patient on
ketogenic diet




Propionylcarnitine (C3) (plasma) 1.2 μmol/L 0.29 μmol/L b0.88 μmol/L
2-Methylcitrate (urine) 0.8 mg/g Cr 0.7 mg/g Cr 0.0–8.0 mg/g Cr
Plasma glycine 517 μmol/L 500 μmol/L 91–482 μmol/L
Plasma isoleucine 15 μmol/L 23 μmol/L 22–107 μmol/L
Plasma leucine 40 μmol/L 75 μmol/L 49–180 μmol/L
Plasma valine 101 μmol/L 101 μmol/L 74–321 μmol/L
Fig. 1. Urine organic acids profiles (Key: 3-OH PA: 3-hydroxypropionic acid, IC: internal standard). Of note our biochemistry
laboratory did not quantitate 3-hydroxypropionate at the time the initial spectrum was obtained. A. Marked excretion of
3-hydroxypropionate with normal excretion of methylcitrate while patient is on ketogenic diet. B. Undetectable 3-hydroxypropionic
acid after initiation of therapy for PA.
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mild and pre- and post-ketogenic diet urine organic acid analyses were not always abnormal (Fig. 1,
Table 1), eluding the identification except for when there was significant metabolic stress (i.e., ketogenic
diet). Additionally, the finding of hyperglycinemia was attributed to NKH negating further evaluation.
Other indicators for additional diagnoses in this patient's history included carnitine deficiency and
multiple episodes of ketonuria and acidosis, which should have prompted the workup that led to the
second diagnosis in this patient sooner.
To our knowledge this is the first case of combined PA and NKH in the same patient. We can only
hypothesize that the change seen in PCCB is mild and may not have manifested in the absence of NKH. The
elevated glycine seen in PA is purposed to be caused by inhibition of the glycine cleavage system by
elevations in propionyl CoA. Of note, related to this case, there are no reports of the PCC enzyme directly
interacting with the glycine cleavage system. However, both are located in the inner mitochondrial
membrane and one could suppose that mutations, even otherwise very mild ones, in both GLDC and PCCB
might affect the inner membrane surface proteins' structure and thus, their function. This may be an
explanation for the very mild biochemical phenotype seen, yet the significant improvement observed with
therapies. Unfortunately, this patient passed away unexpectedly so we do not have samples from him to
test this hypothesis.
Identification of and treatment for PA greatly improved this patient's and his family's quality of life.
Thus, when all symptoms cannot be explained by a single diagnosis, one must consider a more complex
problem, in this case the co-existence of both non-ketotic and ketotic hyperglycinemia. Although the
availability of genetic testing is expanding, good biochemical phenotype will continue to be important to
diagnosing and adequate treating our patients. Furthermore, patients, such as our patient, may help us
understand the pathophysiology of these diseases more thoroughly, if we only consider the possibility.
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